Medical therapies to extend survival in hepatocellular carcinoma.

Robert Gish, Jorge B. Marrero, Myron J. Tong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hepatocellular carcinoma (HCC) is a serious malignancy with 21,000 new cases estimated for 2008. Several common diseases are associated with an increased risk of the development of HCC, including viral hepatitis, cirrhosis, and other chronic liver diseases. Most patients present with advanced disease, and therefore have only limited therapeutic options. However, advancements in screening and surveillance have allowed more patients to be identified and diagnosed with earlier-stage disease, increasing their therapeutic options. Several treatment modalities exist for early- and intermediate-stage disease, including ablative techniques and embolization methods. Additionally, advances in targeted therapy have resulted in the approval of the oral multitargeted tyrosine kinase inhibitor sorafenib, resulting in improved length of survival. In this roundtable discussion, the current epidemic of HCC is addressed, including factors contributing to an increased rate of occurrence. Additionally, the optimal screening and diagnosis of HCC patients is discussed, and the appropriate treatment modalities for each stage of HCC are presented.

Original languageEnglish (US)
JournalClinical advances in hematology & oncology : H&O
Volume6
Issue number8
StatePublished - Aug 2008

Fingerprint

Hepatocellular Carcinoma
Survival
Therapeutics
Protein-Tyrosine Kinases
Hepatitis
Liver Diseases
Fibrosis
Chronic Disease
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Medical therapies to extend survival in hepatocellular carcinoma. / Gish, Robert; Marrero, Jorge B.; Tong, Myron J.

In: Clinical advances in hematology & oncology : H&O, Vol. 6, No. 8, 08.2008.

Research output: Contribution to journalArticle

@article{6d05b169431043f48fb937c988237f41,
title = "Medical therapies to extend survival in hepatocellular carcinoma.",
abstract = "Hepatocellular carcinoma (HCC) is a serious malignancy with 21,000 new cases estimated for 2008. Several common diseases are associated with an increased risk of the development of HCC, including viral hepatitis, cirrhosis, and other chronic liver diseases. Most patients present with advanced disease, and therefore have only limited therapeutic options. However, advancements in screening and surveillance have allowed more patients to be identified and diagnosed with earlier-stage disease, increasing their therapeutic options. Several treatment modalities exist for early- and intermediate-stage disease, including ablative techniques and embolization methods. Additionally, advances in targeted therapy have resulted in the approval of the oral multitargeted tyrosine kinase inhibitor sorafenib, resulting in improved length of survival. In this roundtable discussion, the current epidemic of HCC is addressed, including factors contributing to an increased rate of occurrence. Additionally, the optimal screening and diagnosis of HCC patients is discussed, and the appropriate treatment modalities for each stage of HCC are presented.",
author = "Robert Gish and Marrero, {Jorge B.} and Tong, {Myron J.}",
year = "2008",
month = "8",
language = "English (US)",
volume = "6",
journal = "Clinical Advances in Hematology and Oncology",
issn = "1543-0790",
publisher = "Millennium Medical Publishing, Inc.",
number = "8",

}

TY - JOUR

T1 - Medical therapies to extend survival in hepatocellular carcinoma.

AU - Gish, Robert

AU - Marrero, Jorge B.

AU - Tong, Myron J.

PY - 2008/8

Y1 - 2008/8

N2 - Hepatocellular carcinoma (HCC) is a serious malignancy with 21,000 new cases estimated for 2008. Several common diseases are associated with an increased risk of the development of HCC, including viral hepatitis, cirrhosis, and other chronic liver diseases. Most patients present with advanced disease, and therefore have only limited therapeutic options. However, advancements in screening and surveillance have allowed more patients to be identified and diagnosed with earlier-stage disease, increasing their therapeutic options. Several treatment modalities exist for early- and intermediate-stage disease, including ablative techniques and embolization methods. Additionally, advances in targeted therapy have resulted in the approval of the oral multitargeted tyrosine kinase inhibitor sorafenib, resulting in improved length of survival. In this roundtable discussion, the current epidemic of HCC is addressed, including factors contributing to an increased rate of occurrence. Additionally, the optimal screening and diagnosis of HCC patients is discussed, and the appropriate treatment modalities for each stage of HCC are presented.

AB - Hepatocellular carcinoma (HCC) is a serious malignancy with 21,000 new cases estimated for 2008. Several common diseases are associated with an increased risk of the development of HCC, including viral hepatitis, cirrhosis, and other chronic liver diseases. Most patients present with advanced disease, and therefore have only limited therapeutic options. However, advancements in screening and surveillance have allowed more patients to be identified and diagnosed with earlier-stage disease, increasing their therapeutic options. Several treatment modalities exist for early- and intermediate-stage disease, including ablative techniques and embolization methods. Additionally, advances in targeted therapy have resulted in the approval of the oral multitargeted tyrosine kinase inhibitor sorafenib, resulting in improved length of survival. In this roundtable discussion, the current epidemic of HCC is addressed, including factors contributing to an increased rate of occurrence. Additionally, the optimal screening and diagnosis of HCC patients is discussed, and the appropriate treatment modalities for each stage of HCC are presented.

UR - http://www.scopus.com/inward/record.url?scp=68849109517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849109517&partnerID=8YFLogxK

M3 - Article

C2 - 18833600

AN - SCOPUS:68849109517

VL - 6

JO - Clinical Advances in Hematology and Oncology

JF - Clinical Advances in Hematology and Oncology

SN - 1543-0790

IS - 8

ER -